Performance and Safety Assessment of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Laboratoires Gilbert in Patient With Acute Rhinitis Associated With Nasal Obstruction

NCT ID: NCT06580210

Last Updated: 2025-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

114 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-22

Study Completion Date

2026-06-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this post-market clinical investigation is to assess the performance and the safety of the mechanical decongestant seawater spray enriched with essential oils from Laboratoires Gilbert. The study will evaluate the results of the spray on the acute rhinitis with nasal obstruction over a 7 days period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Rhinitis Nasal Obstruction Rhinosinusitis Rhinopharyngitis Allergic Rhinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Patient ≥ 12 years,
* 2\. Patient with acute rhinitis associated with nasal obstruction during infectious episodes such as rhynopharyngitis (cold), rhinosinusitis, or during non-infectious episodes as allergic rhinitis,
* 3\. a. Informed adult patient who has given written consent prior to any study specific procedure,
* b. Informed minor patients who has given assent and whose legal guardians have given written consent prior to any study specific procedure,
* 4\. Patient able to meet the study requirements (questionnaire completion),
* 5\. Patient affiliated to a social security scheme.

Exclusion Criteria

* 1\. Patient who does not want to participate to the clinical investigation,
* 2\. Hypersensitivity to seawater and/or known allergies to any of the ingredients of the spray,
* 3\. A child with a history of febrile convulsions,
* 4\. Diseases leading to respiratory insufficiency,
* 5\. Patient suffering from nasal deformity or nasal polyps leading to chronic nasal obstruction,
* 6\. Patient on local ans systemic vasoconstrictors, local and systemic corticosteroids and antihistamines, non-steroidal anti-inflammatory (NSAIDs), antibiotics and local antiseptics,
* 7\. Concomitant use of other nasal sprays, essential oils for local nasal use and nsal cream or gel,
* 8\. Patient under guardianship, curatorship of safeguard of justice.
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

EVAMED

OTHER

Sponsor Role collaborator

Laboratoires Gilbert

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pharmacie du Pont Saint Jean

Bayeux, , France

Site Status NOT_YET_RECRUITING

Pharmacie de la Guérinière

Caen, , France

Site Status RECRUITING

Pharmacie de la Force

La Force, , France

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Léa RADDAY

Role: CONTACT

+33 (0)2 31 47 16 61

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dr. Matthieu CHAUVIN

Role: primary

(0)231920763 ext. +33

Benjamin BEAUCHENE, Dr

Role: primary

+33 (0)2 31 82 39 80

Dr Maxime DELARUE

Role: primary

+335-53-58-94-44

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-A01585-38

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ambroxol Spray Sore Throat Study
NCT01361802 COMPLETED PHASE2